Erbitux Cetuximab Injection

1. Indications and Usage
Colorectal Cancer:
Indicated for the treatment of patients with EGFR-expressing, metastatic colorectal cancer as a monotherapy or in combination with irinotecan.
Head and Neck Cancer:
Locally Advanced: Indicated in combination with radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Recurrent/Metastatic: Indicated in combination with platinum-based therapy for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck.
2. Dosage and Administration
Recommended Dosage:
Loading Dose: 400 mg/m² administered as an initial 120-minute intravenous infusion.
Maintenance Dose: 250 mg/m² administered as a 60-minute intravenous infusion once weekly thereafter.
Pre-Medication:
Administer an antihistamine (e.g., diphenhydramine 25–50 mg IV) 1 hour before the first infusion.
Administration:
Do not administer as an intravenous push or bolus. Use a non-PVC infusion set.
3. Mechanism of Action
EGFR Inhibition:
Cetuximab binds to the extracellular domain of the epidermal growth factor receptor (EGFR) with higher affinity than the natural ligands.
Physiological Effect:
Receptor occupancy prevents phosphorylation and activation of receptor-associated kinases, thereby inhibiting cell growth, inducing apoptosis, decreasing metastasis and angiogenesis, and increasing tumor cell sensitivity to the cytotoxic effects of radiation and some chemotherapeutic agents.
4. Safety and Warnings
Infusion-Related Reactions:
Severe, potentially fatal reactions (e.g., acute pulmonary edema, hypotension, bronchospasm) can occur. Up to 90% occur during the first infusion. Monitor patients closely during and for at least 1 hour after infusion.
Pulmonary Toxicity:
Interstitial lung disease (ILD) has been reported. Discontinue cetuximab in patients with severe or progressive pulmonary symptoms.
Dermatologic Toxicity:
Acneiform rash is very common and correlates with efficacy. Severe skin reactions (e.g., necrosis, bullous eruptions) may occur.
Embryo-Fetal Toxicity:
Can cause fetal harm. Advise females of reproductive potential to use effective contraception.
5. Adverse Reactions
Most Common:
Acneiform rash, fatigue, infection, diarrhea, nausea, vomiting, anorexia, and headache.
Electrolyte Disturbances:
Hypomagnesemia occurs frequently due to renal magnesium wasting. Monitor serum magnesium levels.
6. Drug Interactions
Radiation Therapy:
Concomitant use with radiation therapy has been associated with increased cardiopulmonary toxicity (cardiac arrest, cardiopulmonary arrest).
Chemotherapy:
Pharmacokinetic interactions with irinotecan or platinum agents have not been definitively established, but clinical monitoring is required.
7. Pharmaceutical Information
Storage:
Store at 2°C to 8°C (36°F to 46°F). Do not freeze or shake vigorously. Protect from light.